Saxony Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Saxony Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227K	Buy	+457	New	+$203K	0.1%	158

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Saxony Capital Management's VRTX Position: Q2 2026 in Review

Saxony Capital Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 457 shares worth $227K. The stake represents 0.1% of the portfolio and ranks #158 among its holdings.

379 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Saxony Capital Management held 457 shares of Vertex Pharmaceuticals worth $227K as of Q2 2026.
Vertex Pharmaceuticals was a new Saxony Capital Management position in Q2 2026.
Vertex Pharmaceuticals made up 0.1% of Saxony Capital Management's portfolio in Q2 2026, its #158 holding.
379 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Saxony Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.